Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 148 participants.

Also called NCT02162550

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 148 participants (planned count) (from the registry)
Sponsor
Phoenix VA Health Care System (from the registry)
Registry
  • NCT NCT02162550
Other papers using this trial's data
  • The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study Diabetes care, 2021-06 DOI, PubMed 33495294, PMC8247511 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02162550. Randomized; quadruple masking; primary purpose treatment. Start 2014-06 (registry gives no type); primary completion 2019-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus
Intervention (Drug)
Bydureon
Intervention (Drug)
placebo
Lead sponsor
Phoenix VA Health Care System (class: US federal agency)

Record details

Record id
cardio:ct-nct02162550
Content hash
76c86a40aa7f65e8787f099fda285b10a7dc364b4b817acf4d63c2337229c59c